Psoriasis treated with ursodeoxycholic acid: Three case reports

Clinical and Experimental Dermatology

Volumn 32, Issue 4, 2007, Pages 398-400

  Itoh, S ^a   Kono, M ^a   Akimoto, T ^a  

^a Chiba Central Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COAL TAR; COLECALCIFEROL; CORTICOSTEROID; PIOGLITAZONE; SALICYLIC ACID; URSODEOXYCHOLIC ACID;

ABDOMEN; ADULT; AGED; ARTICLE; BACK; BUTTOCK; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; JAPANESE; LIVER BIOPSY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SKIN BIOPSY; SKIN DEFECT;

AGED; BIOPSY; CHOLAGOGUES AND CHOLERETICS; FATTY LIVER; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 34249688590     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02401.x     Document Type: Article

References (10)

1. Kumar O, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol 2001 16 : 3 14.
2. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease. a spectrum of clinical and pathological severity. Gastroenterology 1999 116 : 1413 19.
3. Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003 48 : 2182 6.
4. Ikai K. Psoriasis and the arachidonic acid cascade. J Dermatol Sci 1999 21 : 135 46.
5. Andersen S, Sjursen W, Laegreid A et al. Elevated expression of human nonpancreatic phospholipase A2 in psoriatic tissue. Inflammation 1994 18 : 1 12.
6. Chiba H, Michibata H, Wakimoto K et al. Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2δ, induced in psoriatic skin. J Biol Chem 2004 279 : 12890 7.
7. Kano M, Shoda J, Irimura T et al. Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipase A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. Hepatology 1998 28 : 302 13.
8. Ikegami T, Matsuzaki Y, Fukushima S et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005 41 : 896 905.
9. Gyurcsovics K, Bertók L. Pathophysiology of psoriasis: coping endotoxins with bile acid therapy. Pathophysiology 2003 10 : 57 61.
10. Yamaguchi Y, Itami S, Nishida K et al. Taurin-conjugated ursodeoxycholic acid has a reversible inhibitory effect on human keratinocyte growth. J Dermatol Sci 1998 18 : 35 42.